Kate Rowley

Cellesce Ltd. develops bioprocessing technology for organoids. Its products include colorectal cancer organoids and organoids of other human organs. The company was founded in 2013 and is headquartered in Cardiff, the United Kingdom.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.

Cellesce Ltd. develops bioprocessing technology for organoids. Its products include colorectal cancer organoids and organoids of other human organs. The company was founded in 2013 and is headquartered in Cardiff, the United Kingdom.

Cellesce Ltd. develops bioprocessing technology for organoids. Its products include colorectal cancer organoids and organoids of other human organs. The company was founded in 2013 and is headquartered in Cardiff, the United Kingdom.

Cellesce Ltd. develops bioprocessing technology for organoids. Its products include colorectal cancer organoids and organoids of other human organs. The company was founded in 2013 and is headquartered in Cardiff, the United Kingdom.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.